Search results for "ERLOTINIB"

Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians.

2015

Abstract: In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients, selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role in the treatment, detection, and management of common toxicities and…

Impact of tumor heregulin mRNA expression on outcome of patients with advanced/metastatic squamous NSCLC treated with lumretuzumab, a glycoengineered…

2016

Impact of nutritional status on the pharmacokinetics of erlotinib in rats

2015

Malnourishment is a complex condition in which physiopathological changes take place in multiple systems as a result of energy, protein and nutrient deficiency. The purpose of this study was to evaluate, using an experimental animal model, the impact of nutritional status on the pharmacokinetic profile of erlotinib, a reversible, highly selective, human epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor. Two groups of rats -WN (well-nourished) and UN (undernourished) - were fed with different diets for 23-26 days. Rats were assigned randomly to one of three erlotinib treatments (n = 42) consisting of a single dose administered intravenously (i.v.), via oral solution or v…

Levofloxacin effect on erlotinib absorption. Evaluation of the interaction in undernutrition situations through population pharmacokinetic analysis i…

2017

The main objective of this study was to develop a pharmacokinetic model in order to describe the intestinal absorption of erlotinib in rat and to quantify the interaction of levofloxacin on this process in well- and under-nourished rats. Absorption studies were performed in male Wistar rats. Concentration-time profiles in proximal and distal intestine were analysed through non-linear mixed effect modelling using the NONMEM software version 7.3. Simulations were performed in order to explore the influence of covariates on the apparent absorption rate constant. A passive absorption and an active secretion process best-described erlotinib absorption from lumen to enterocyte. The developed mode…

Cutaneous Toxicity Induced by Hibiscus Tea in a Patient Treated with Erlotinib

2017

Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?

2018

In the N Engl J Med , Soria and colleagues have recently reported the results of the phase III randomized FLAURA trial (1), comparing osimertinib with first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib or erlotinib in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) and activating EGFR -mutations.

Show me your signaling– and I’ll tell you who you are

2009

See Article, pages 725–733Cancer research and therapy have come a long way:the field started out in search of a ‘‘magic bullet” accord-ing to Paul Ehrlich’s theory, and was hoping to identifya target which was pivotal to signaling survival in trans-formed cells. Indeed, certain diseases with monocausalmutations were identified, and targeting of the muta-tional products has helped in the design of treatmentstrategies. In chronic myeloid leukemia (CML), the con-stitutive activation of the tyrosine kinase BCR-ABL ispathognomonic [1], and multiple BCR-ABL kinaseinhibitors (e.g. imatinib mesylate, dasatinib, nilotinib)have been developed and successfully used in the treat-ment of CML offering near-…

Impact of Undernourishment on the Pharmacokinetics of Erlotinib and Gefitinib in Rats

2017

The relationship between nutritional status and pharmacokinetics has been previously studied for classical anticancer drugs, but this relationship remains unexplored for modern therapies involving targeted drugs and new administration routes. In this context, the main objective of this thesis was to evaluate, in undernourished and well-nourished Wistar rats, the impact of undernourishment on the pharmacokinetics of erlotinib and gefitinib, two novel orally administered targeted-drugs. The research investigation was divided into three main experiments: • Evaluation of analytical and molecular alterations associated with undernourishment • In situ intestinal perfusion studies • In vivo pharma…

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

2020

Abstract Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated radiographically, however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR promotes the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the cells become resistant with a mesenchymal phenotype. As EDN1 and its receptor (EDNR) is linked to cancer progression, EDNR-antagonists have been evaluated in several clinical trials with disappointing results. These trials were based on a hypothesis that…

versamenti pleurici maligni: dalle analisi genetiche al trattamento chirurgico

2014

Introduzione: Il versamento pleurico maligno è una complicanza piuttosto frequente di numerosi tumori sia di origine intratoracica che a partenza da organi extratoracici. Il carcinoma polmonare da solo è la seconda causa più comune di versamento pleurico maligno in pazienti con età superiore a 50 anni. Spesso sono pazienti con patologia in fase avanzata con sopravvivenza media non superiore a 8-10 mesi. Nel ricercare nuove strategie terapeutiche, potenziali e interessanti vantaggi sembrano offrirci gli studi in ambito biomolecolare soprattutto per quanto concerne la presenza del gene per l’epidermal growth factor receptor (EGFR) presente a livello del cromosoma 7 in pazienti affetti da tumo…